The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary edema, noncardiogenic (NCPE)
The respective role of tocolytic agents, underlying cardiac disease, fluid overload, and preeclampsia must be evaluated
Publications
Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births.
Journal of perinatal medicine 2014 Sep;42;585-9 — 2014 Sep — 585-9
A comparison of three tocolytics for preterm labor: a randomized clinical trial.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2014 May;27;801-6 — 2014 May — 801-6
Magnesium sulfate tocolysis and pulmonary edema: the drug or the vehicle?
American journal of obstetrics and gynecology 2005 May;192;1430-2 — 2005 May — 1430-2
The risk of pulmonary edema and colloid osmotic pressure changes during magnesium sulfate infusion.
American journal of obstetrics and gynecology 1993 Dec;169;1566-71 — 1993 Dec — 1566-71